ArticleSmall science2024
Bright Semiconductor Quantum Dots Shed New Light on Precision Nanomedicine for Various Diseases.
Article in Small science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Indium phosphide quantum dots: advanced synthesis, surface engineering, and biomedical applications in imaging, sensing, and therapy.RSC advances · 2026Review
- Nucleation-Controlled Doping of II-VI Semiconductor Nanocrystals Mediated by Magic-Sized Clusters.Small science · 2025Article
- Shedding light on vascular imaging: the revolutionary role of nanotechnology.Journal of nanobiotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomaterials with diagnostic and therapeutic functions have exciting potential to reshape the landscape of precision medicine. Impressive progress has been made toward the design and production of innovative theranostic nanomaterials that improve disease care, motivated by their ability to simultaneously provide diagnostic information and therapeutic benefits. Herein, the state-of-the-art theranostic semiconductor quantum dots (QDs) are summarized, and the diverse types of QDs designed for the diagnosis and treatment of different diseases are discussed. The opportunities and benefits of QDs are highlighted throughout using in vitro and in vivo examples aimed at addressing various clinical challenges, including cancer, vascular dysfunctions, microbial infections, and medical tattoos. Over the past several years, this area has experienced enormous growth, particularly in preclinical animal imaging and therapy, which has brought the field closer to reaching human patients. Unfortunately, several barriers to clinical translation remain. Therefore, in addition to summarizing the key results from previous in vivo studies, the lessons learned from these studies are synthesized, perspective on the future steps needed for both fundamental studies and the clinical translation of theranostic QD nanotechnology to inform future QD design is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.